Marina Biotech To Present New Findings At Annual Conference

Biotech Investing

Marina Biotech (OTCQB: MRNA) announced it will present an update at the Society of Toxicology 56th Annual Meeting in March.

Marina Biotech (OTCQB:MRNA) announced it will present an update at the Society of Toxicology 56th Annual Meeting in March.
As quoted in the press release:

Dr. Osmond D’Cruz, co-author of the abstract, will present the findings of the safety and tolerability of an RNAi therapeutic in Familial Adenomatous Polyposis (START-FAP) proof of concept clinical trial with CEQ508. The late breaking poster outlines a dose escalating Phase 1 trial conducted with with daily, oral administration of CEQ508 over 28 days of FAP patients.
Joseph Ramelli, CEO of Marina Biotech, stated, “The completion of this trial is a great milestone for Marina Biotech. Our clinical results continue to prove that our proprietary tkRNAi delivery platform is a safe and effective oral delivery of siRNA. This is the only oral delivery platform for oligotherapeutics and we look forward to continuing development of CEQ508 for FAP as well as expansion of the platform to other indications.”
1“Safety and Tolerability of Live-Attenuated Bacteria CEQ508 Engineered to Produce and Deliver Short-Hairpin RNA-Mediated Knockdown of β Catenin in the Gastrointestinal Mucosa of Patients with Familial Adenomatous Polyposis, authored by O. J. D’Cruz, L. Hwang, K. Ng, A. T. Fong, D. Nam, W. Wang, V. Trieu.”
About Marina Biotech
Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103 — next generation celecoxib — which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at

Click here to read the full press release.

The Conversation (0)